Public Profile

Fagron

Fagron, a leading global player in the pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe, North America, and Latin America. Founded in 1990, the company has established itself as a pioneer in customised medicines, focusing on compounding and innovative pharmaceutical solutions tailored to individual patient needs. Fagron's core offerings include a diverse range of pharmaceutical products and services, such as sterile and non-sterile compounding, as well as advanced drug delivery systems. What sets Fagron apart is its commitment to quality and innovation, ensuring that healthcare professionals have access to tailored therapies that enhance patient outcomes. With a strong market position and a reputation for excellence, Fagron continues to achieve significant milestones in the pharmaceutical sector, reinforcing its status as a trusted partner in personalised medicine.

DitchCarbon Score

How does Fagron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

59

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Fagron's score of 59 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

99%

Let us know if this data was useful to you

Fagron's reported carbon emissions

In 2024, Fagron reported total greenhouse gas emissions of approximately 293,227,000 kg CO2e. This includes 3,871,000 kg CO2e from Scope 1 emissions, 6,554,000 kg CO2e from Scope 2 emissions (market-based), and a significant 282,802,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, committing to a 42% reduction in absolute Scope 1 and 2 emissions by 2030, using 2021 as the baseline year. Additionally, Fagron aims to decrease absolute Scope 3 emissions by 25% within the same timeframe. By 2027, the company plans for 60% of its suppliers, based on emissions from purchased goods and services, to have science-based targets in place. These commitments align with industry standards for climate action and demonstrate Fagron's dedication to sustainability and reducing its environmental impact.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
2,818,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
8,200,000
0,000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 3
2,477,000
000,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Fagron's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Fagron is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Fagron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Harrow, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Bausch Health Cos

CA
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Allergan

US
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Neoleukin Therapeutics, Inc.

US
Health and social work services (85)
Updated 2 months ago

Ocular Therapeutix, Inc.

US
Health and social work services (85)
Updated 24 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers